Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Or Refractory Non-Hodgkin Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT07133997
What this trial is testing

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

Who this might be right for
Recurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia
City of Hope Medical Center 26
Testing effectiveness (Phase 2)Ended earlyNCT00051701
What this trial is testing

Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkins Lymphoma
Genzyme, a Sanofi Company 61
Large-scale testing (Phase 3)Study completedNCT01461928
What this trial is testing

A Study Comparing Maintenance Subcutaneous Rituximab With Observation Only in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to Rituximab-based Immunochemotherapy Induction and 2-year Maintenance With Subcutaneous Rituximab

Who this might be right for
Non-Hodgkin's Lymphoma
Hoffmann-La Roche 692
Testing effectiveness (Phase 2)WithdrawnNCT00298467
What this trial is testing

MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma

Who this might be right for
Lymphoma, Large-Cell
Bristol-Myers Squibb 45
Testing effectiveness (Phase 2)Study completedNCT01472887
What this trial is testing

SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients

Who this might be right for
Diffuse Large B-cell Lymphoma
Sanofi 61
Testing effectiveness (Phase 2)Looking for participantsNCT07271121
What this trial is testing

Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL

Who this might be right for
Non-Hodgkin Lymphoma Refractory/ Relapsed
King Hussein Cancer Center 26
Early research (Phase 1)UnknownNCT05398614
What this trial is testing

SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies

Who this might be right for
T-ALLLymphoma, T-Cell
Hebei Senlang Biotechnology Inc., Ltd. 18
Early research (Phase 1)Study completedNCT00012181
What this trial is testing

Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas

Who this might be right for
Recurrent Childhood Brain Stem GliomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral Astrocytoma+19 more
National Cancer Institute (NCI) 30
Early research (Phase 1)Looking for participantsNCT05052528
What this trial is testing

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
University of California, Davis 36
Testing effectiveness (Phase 2)Study completedNCT00868608
What this trial is testing

Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma

Who this might be right for
Lymphoma
Pfizer 81
Testing effectiveness (Phase 2)UnknownNCT02471391
What this trial is testing

ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)

Who this might be right for
Mantle Cell Lymphoma
Peter MacCallum Cancer Centre, Australia 37
Testing effectiveness (Phase 2)Active Not RecruitingNCT06035497
What this trial is testing

Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Who this might be right for
Relapsed or Refractory T-cell Lymphomas
Bristol-Myers Squibb 85
Testing effectiveness (Phase 2)Looking for participantsNCT07523555
What this trial is testing

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLLRelapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia+4 more
Beijing Biotech 96
Testing effectiveness (Phase 2)Study completedNCT05844956
What this trial is testing

DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)

Who this might be right for
Lymphoma, Non-Hodgkin
Dizal Pharmaceuticals 17
Testing effectiveness (Phase 2)Study completedNCT03010358
What this trial is testing

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

Who this might be right for
AnemiaB-Cell Prolymphocytic LeukemiaGrade 1 Follicular Lymphoma+11 more
Alexey Danilov, MD 24
Early research (Phase 1)Looking for participantsNCT06445517
What this trial is testing

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

Who this might be right for
Advanced Solid TumorsRelapsed/Refractory B-cell Lymphoma
InSilico Medicine Hong Kong Limited 60
Testing effectiveness (Phase 2)Ended earlyNCT01799889
What this trial is testing

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Chronic Lymphocytic LeukemiaMantle Cell LymphomaDiffuse Large B-cell Lymphoma+2 more
Gilead Sciences 326
Early research (Phase 1)Study completedNCT02613598
What this trial is testing

Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma

Who this might be right for
Hodgkin's LymphomaLymphoma, Non-Hodgkin
University of Michigan Rogel Cancer Center 15
Not applicableEnded earlyNCT00904514
What this trial is testing

Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 241
Testing effectiveness (Phase 2)Study completedNCT05008055
What this trial is testing

Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
AstraZeneca 30
Next Page